Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain

[at noodls] – Abstral® was approved in the U.S. in 2011 and is the first and only fentanyl sublingual tablet for the management of breakthrough cancer pain in opioid tolerant patients. Abstral® product launch targeted … more

View todays social media effects on GALE

View the latest stocks trending across Twitter. Click to view dashboard

See who Galena is hiring next, click here to view